Ventria Bioscience

Ventria Bioscience is a biotech company with a focus on human nutrition and human therapeutics. The Company's core technology is a plant-based protein production system called ExpressTec. Ventria completed construction of its bioprocessing facility in Junction City, Kansas and is expanding its operations in Kansas. Ventria's product pipeline is based on recombinant lactoferrin and lysozyme for use in medical foods, bioprocessing, cell culture and as a topical anti-infective. These proteins show promise as a supplement to oral rehydration therapy and promote the growth of healthy gut flora. Ventria invites other researchers to have access to its recombinant human lactoferrin and recombinant human lysozyme through a program called BioShare.

Novita Therapeutics, LLC

Novita Therapeutics was founded in 2009 to develop new and innovative medical devices and pharmaceuticals for the cardiovascular, renal, and gastrointestinal markets. Novita intends to identify nascent product opportunities and carry out early stage product development. When a product reaches a “proof-of-concept” stage where its value can be clearly demonstrated, Novita intends to sell, license, or spinout that product into a separate company that can carry the product forward through clinical development to commercial launch.

CritiTech, Inc.

CritiTech conducts research and development into the production of fine-particle compounds. The Company is expanding its operations to become a developer and manufacturer of fine-particle pharmaceutical compounds servicing both the drug manufacturing and biotechnology industry.

VasoGenix Pharmaceuticals, Inc.

VasoGenix Pharmaceuticals is a preclinical stage pharmaceutical company focused on the development and commercialization of synthetic agonist analogs of Calcitonin Gene Related Peptide (CGRP) to treat heart failure severe enough to require hospitalization.  The Company’s technology was recently described by NIH reviewers as “highly innovative” and “a paradigm shifting therapy in the treatment of heart failure.”  The analogs will be delivered intravenously and in a proprietary biodegradable controlled release delivery system, and are expected to reduce hospital length of stay and re-hospitalization rates, thereby saving the healthcare system billions annually.

©2019 All rights reserved. Wichita Technology Corporation

Website by 360ideas | Sitemap |

(316) 651-5900